Skip to main content
SpringerLink
Log in

Analysis of cathepsin D in human breast cancer: Usefulness of the processsed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The relative amounts of the precursor (52 kDa) and processed (31,27 kDa) forms of cathepsin D have been analyzed by Western blotting in biopsied breast tissue cytosols from 134 lesions from invasive breast cancer patients, 24 lesions from patients with ductal carcinoma in situ (DCIS), 227 lesions from benign breast disease patients, and 28 lesions from normal control subjects. The mean relative percentage amount of the 31 kDa form was significantly increased (p<0.001) in the invasive breast cancer group compared to the other three groups. In addition, the mean relative percentage amount of the 31 kDa form was significantly increased (p<0.05) in node-positive compared to node-negative breast cancer patients. In the benign breast disease group, patients with proliferative-type disease had a significantly increased (p=0.02) mean relative percentage amount of the 31 kDa form of cathepsin D compared to patients with nonproliferative-type disease. Invasive breast cancer patients were followed for up to 75 months to determine if the relative percentage amount of the 31 kDa form of cathepsin D was predictive of disease-free and overall survival. Although the amount of the 31 kDa form was not predictive of disease-free survival, patients in the ‘high’ 31 kDa group (>18) were significantly (p<0.05) more likely to die than patients in the ‘low’ 31 kDa group (≤18%). The 12 patients who died were all node-positive and in the high 31 kDa group. It thus appears that the relative amount of the processed, active 31 kDa form of cathepsin D is a useful prognostic indicator, at least in node-positive breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barett AJ: Cellular proteolysis. An overview. Ann NY Acad Sci 674: 1–15, 1992

  2. Leto G, Gebbia N, Rausa L, Tumminello, FM: Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res 12: 235–240, 1992

    Google Scholar 

  3. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet J-P, Rochefort H: Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14: 642–650, 1996

    Google Scholar 

  4. Westley BR and May FEB: Cathepsin D and breast cancer. Eur J Cancer 32A: 15–24, 1996

    Google Scholar 

  5. Schultz DC, Bazel S, Wright LM, Tucker S, Lange MK, Tachovsky T, Longo S, Niedbala S, Alhadeff JA: Western blotting and enzymatic activity analysis of cathepsin D in breast cancer and benign breast disease and of normal controls. Cancer Res 54: 48–54, 1994

    Google Scholar 

  6. Bazel S, Ferry KV, Shoarinejad F, Laury-Kleintop LD, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA: Analysis of breast tissue cathepsin D isoforms from patients with breast cancer, benign breast disease and from normal controls. Intern J Oncol 5: 847–853, 1994

    Google Scholar 

  7. Laury-Kleintop LD, Coronel EC, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA: Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines. Breast Cancer Res Treat 35: 211–220, 1995

    Google Scholar 

  8. Wright LM, Levy ES, Patel NP, Alhadeff JA: Purification and characterization of cathepsin D from normal human breast tissue. J Protein Chem 16: 171–181, 1997

    Google Scholar 

  9. Bazel S, Alhadeff JA: Characterization of purified cathepsin D from malignant human breast tissue. Intern J Oncol 14: 315–319, 1999

    Google Scholar 

  10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951

    Google Scholar 

  11. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, Brunner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of nodenegative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9–16, 1998

    Google Scholar 

  12. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM: Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79: 300–307, 1999

    Google Scholar 

  13. Ferno M, Baldetorp B, Borg A, Brouillet JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D: Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A: 2042–2048, 1994

    Google Scholar 

  14. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC, Osborne CK: Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467–474, 1994

    Google Scholar 

  15. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H: Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer 29A: 1248–1251, 1993

    Google Scholar 

  16. Gohring UJ, Scharl A, Thelen U, Ahr A, Crombach G, Titius BR: Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J Clin Pathol 49: 57–64, 1996

    Google Scholar 

  17. Aaltonen M, Lipponen P, Kosma V-M, Aaltomaa S, Syrjanen K: Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res 15: 1033–1038, 1995

    Google Scholar 

  18. Okamura K, Kobayashi I, Matsuo K, Kiyoshima T, Yamamoto K, Miyoshi A, Sakai H: Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analyzed by computer image analyzer: correlation with histological grade and metastatic behavior. Histopathology 31: 540–548, 1997

    Google Scholar 

  19. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, and Morales AR: Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in nodenegative breast cancer. Hum Pathol 27: 890–895, 1996

    Google Scholar 

  20. Bevilacqua P, Boracchi P, Gasparini G: Prognostic indicators for early-stage breast carcinoma. Part II: Value of Cathepsin D expression, detected by immunocytochemistry A multiparametric study. Intern J Oncol 5: 559–564, 1994

    Google Scholar 

  21. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25: 857–862, 1994

    Google Scholar 

  22. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V-M: Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917–922, 1997

    Google Scholar 

  23. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visona A, Dante S: Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A: 671–677, 1995

    Google Scholar 

  24. Glikman P, Rogozinski A, Mosto J, Pollina A, Garbovesky C, Levy, C: Relationship between cathepsin-D and other prognostic factors in human breast cancer. Tumori 83: 688–691, 1997

    Google Scholar 

  25. Gohring U-J, Scharl A, Thelen U, Ahr A, Crombach G: Comparative prognostic value of cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. Anticancer Res 16: 1011–1017, 1996

    Google Scholar 

  26. Nikolic-Vukosavljevic D, Grujic-Adanja G, Nastic-Miric D, Brankovic-Magic M, Jovanovic D, Polic DJ, Mitrovic L: Cathepsin D: association between TN-stage and steroid receptor status of breast carcinoma. Tumor Biology 19: 329–334, 1998

    Google Scholar 

  27. Ardavanis A, Gerakini F, Amanatidou A, Scorilas A, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis, I: Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance. Anticancer Res 17: 3665–3670, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. Luke's Hospital and Health Network, Bethlehem, PA, USA

    Lee B. Riley, Marianne K. Lange, Richard J. Browne & Peter J. Cochrane

  2. Department of Chemistry, Division of Biochemical Sciences, Lehigh University, MTC, Bethlehem, PA, USA

    Ik-Joon Choi & Jack A. Alhadeff

  3. Regional Cancer Center, Bethlehem, PA, USA

    Barbara Davis

  4. Research Institute, St. Luke's Hospital and Health Network, Bethlehem, PA, USA

    Stephen Arcona

Authors
  1. Lee B. Riley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marianne K. Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard J. Browne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter J. Cochrane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ik-Joon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stephen Arcona
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jack A. Alhadeff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riley, L.B., Lange, M.K., Browne, R.J. et al. Analysis of cathepsin D in human breast cancer: Usefulness of the processsed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Res Treat 60, 173–179 (2000). https://doi.org/10.1023/A:1006394401199

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006394401199

Search

Navigation